Literature DB >> 11136694

Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation.

G W Cockerill1, T Y Huehns, A Weerasinghe, C Stocker, P G Lerch, N E Miller, D O Haskard.   

Abstract

BACKGROUND: Although there is strong evidence that plasma HDL levels correlate inversely with the incidence of coronary artery disease, the precise mechanism(s) for the protective effect of HDLs remains unclear. We recently showed that HDLs inhibit endothelial cell expression of cytokine-induced leukocyte adhesion molecules in vitro. Our study therefore sought to test the hypothesis that elevating the level of circulating HDLs would inhibit endothelial cell activation in vivo. METHODS AND
RESULTS: We used a porcine model of inflammation previously established in our laboratory, in which the level of vascular endothelial cell expression of E-selectin in interleukin (IL)-1alpha-induced skin lesions was measured by the uptake of a radiolabeled anti-E-selectin antibody (1.2B6). Porcine plasma HDL levels were elevated by use of a bolus injection of reconstituted discoidal HDL (recHDL). These particles resemble nascent HDL particles in shape and contain apolipoprotein A-I as the sole protein and soybean phosphatidylcholine as the sole phospholipid. We found that recHDLs inhibited the expression of IL-1alpha-induced E-selectin by porcine aortic endothelial cells in vitro, confirming that the inhibitory effect is conserved with synthetic HDLs and demonstrating that the phenomenon is not restricted to human endothelial cells. In vivo, elevating the circulating level of HDLs approximately 2-fold led to significant inhibition of basal and IL-1alpha-induced E-selectin expression by porcine microvascular endothelial cells.
CONCLUSIONS: These observations demonstrate the potential anti-inflammatory action of HDLs and provide support for the further investigation of the mechanisms underlying the inhibitory effects of HDLs on endothelial cell activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136694     DOI: 10.1161/01.cir.103.1.108

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  55 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

Review 3.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 4.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 5.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

Review 6.  Cardioprotective functions of HDLs.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2013-06-27       Impact factor: 5.922

7.  Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study.

Authors:  Archana Singh-Manoux; David Gimeno; Mika Kivimaki; Eric Brunner; Michael G Marmot
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-30       Impact factor: 8.311

8.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

9.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation.

Authors:  Hiroyasu Sato; Yoshitaka Taketomi; Yuki Isogai; Seiko Masuda; Tetsuyuki Kobayashi; Kei Yamamoto; Makoto Murakami
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.